A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D Armstrong, Bridget C. Marcinkowski, Lureen S. Ojalvo, David B. Kanne, Elizabeth Jaffee, Thomas W. Dubensky, Leisha A. Emens

Research output: Contribution to journalArticle

Abstract

Stimulator of interferon genes (STING) signaling induces IFNb production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigenspecific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2 breast tumors. ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100% of nontolerant parental FVB/N mice. In contrast, ADU S-100 did not sufficiently prime HER-2- specific CD8+ T cells in tolerant neu/N mice, resulting in only delayed tumor growth and tumor clearance in 10% of the mice. No differences in IFNb production, DC priming, or HER-2- specific CD8+ T-cell trafficking were detected between FVB/N and neu/N mice. However, activation and expansion of HER-2- specific CD8+ T cells were defective in neu/N mice. Immune cell infiltrates of untreated tumor-bearing neu/N mice expressed high numbers of PD1 and OX40 receptors on their CD8+ T cells, and PD-L1 was highly expressed on both myeloid and tumor cells. Modulating PD-L1 and OX40 receptor signaling combined with intratumoral ADU S-100 administration enhanced HER-2-specific CD8+ T-cell activity, clearing tumors in 40% of neu/N mice. Thus, intratumoral STING agonists could potently prime tumor antigen-specific CD8+ T-cell responses, and adding PD-L1 blockade and OX40 receptor activation can overcome antigen-enforced immune tolerance to induce tumor regression.

Original languageEnglish (US)
Pages (from-to)468-479
Number of pages12
JournalCancer immunology research
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

OX40 Receptor
Interferons
Immunity
T-Lymphocytes
Growth
Genes
Neoplasms
Dendritic Cells
Programmed Cell Death 1 Receptor
Immune Tolerance
Tumor Microenvironment
Neoplasm Antigens
Myeloid Cells

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. / Foote, Jeremy B.; Kok, Marleen; Leatherman, James M.; Armstrong, Todd D; Marcinkowski, Bridget C.; Ojalvo, Lureen S.; Kanne, David B.; Jaffee, Elizabeth; Dubensky, Thomas W.; Emens, Leisha A.

In: Cancer immunology research, Vol. 5, No. 6, 01.06.2017, p. 468-479.

Research output: Contribution to journalArticle

Foote, Jeremy B. ; Kok, Marleen ; Leatherman, James M. ; Armstrong, Todd D ; Marcinkowski, Bridget C. ; Ojalvo, Lureen S. ; Kanne, David B. ; Jaffee, Elizabeth ; Dubensky, Thomas W. ; Emens, Leisha A. / A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. In: Cancer immunology research. 2017 ; Vol. 5, No. 6. pp. 468-479.
@article{14eb4bcf96bc4c60bf99b601b613b066,
title = "A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice",
abstract = "Stimulator of interferon genes (STING) signaling induces IFNb production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigenspecific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2 breast tumors. ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100{\%} of nontolerant parental FVB/N mice. In contrast, ADU S-100 did not sufficiently prime HER-2- specific CD8+ T cells in tolerant neu/N mice, resulting in only delayed tumor growth and tumor clearance in 10{\%} of the mice. No differences in IFNb production, DC priming, or HER-2- specific CD8+ T-cell trafficking were detected between FVB/N and neu/N mice. However, activation and expansion of HER-2- specific CD8+ T cells were defective in neu/N mice. Immune cell infiltrates of untreated tumor-bearing neu/N mice expressed high numbers of PD1 and OX40 receptors on their CD8+ T cells, and PD-L1 was highly expressed on both myeloid and tumor cells. Modulating PD-L1 and OX40 receptor signaling combined with intratumoral ADU S-100 administration enhanced HER-2-specific CD8+ T-cell activity, clearing tumors in 40{\%} of neu/N mice. Thus, intratumoral STING agonists could potently prime tumor antigen-specific CD8+ T-cell responses, and adding PD-L1 blockade and OX40 receptor activation can overcome antigen-enforced immune tolerance to induce tumor regression.",
author = "Foote, {Jeremy B.} and Marleen Kok and Leatherman, {James M.} and Armstrong, {Todd D} and Marcinkowski, {Bridget C.} and Ojalvo, {Lureen S.} and Kanne, {David B.} and Elizabeth Jaffee and Dubensky, {Thomas W.} and Emens, {Leisha A.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/2326-6066.CIR-16-0284",
language = "English (US)",
volume = "5",
pages = "468--479",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

AU - Foote, Jeremy B.

AU - Kok, Marleen

AU - Leatherman, James M.

AU - Armstrong, Todd D

AU - Marcinkowski, Bridget C.

AU - Ojalvo, Lureen S.

AU - Kanne, David B.

AU - Jaffee, Elizabeth

AU - Dubensky, Thomas W.

AU - Emens, Leisha A.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Stimulator of interferon genes (STING) signaling induces IFNb production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigenspecific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2 breast tumors. ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100% of nontolerant parental FVB/N mice. In contrast, ADU S-100 did not sufficiently prime HER-2- specific CD8+ T cells in tolerant neu/N mice, resulting in only delayed tumor growth and tumor clearance in 10% of the mice. No differences in IFNb production, DC priming, or HER-2- specific CD8+ T-cell trafficking were detected between FVB/N and neu/N mice. However, activation and expansion of HER-2- specific CD8+ T cells were defective in neu/N mice. Immune cell infiltrates of untreated tumor-bearing neu/N mice expressed high numbers of PD1 and OX40 receptors on their CD8+ T cells, and PD-L1 was highly expressed on both myeloid and tumor cells. Modulating PD-L1 and OX40 receptor signaling combined with intratumoral ADU S-100 administration enhanced HER-2-specific CD8+ T-cell activity, clearing tumors in 40% of neu/N mice. Thus, intratumoral STING agonists could potently prime tumor antigen-specific CD8+ T-cell responses, and adding PD-L1 blockade and OX40 receptor activation can overcome antigen-enforced immune tolerance to induce tumor regression.

AB - Stimulator of interferon genes (STING) signaling induces IFNb production by intratumoral dendritic cells (DC), driving T-cell priming and recruitment into the tumor microenvironment (TME). We examined to what extent preexisting antigenspecific tolerance influenced the efficacy of in situ delivery of a potent STING-activating cyclic dinucleotide (CDN), ADU S-100, against established HER-2 breast tumors. ADU S-100 induced HER-2-specific CD8+ T-cell priming and durable tumor clearance in 100% of nontolerant parental FVB/N mice. In contrast, ADU S-100 did not sufficiently prime HER-2- specific CD8+ T cells in tolerant neu/N mice, resulting in only delayed tumor growth and tumor clearance in 10% of the mice. No differences in IFNb production, DC priming, or HER-2- specific CD8+ T-cell trafficking were detected between FVB/N and neu/N mice. However, activation and expansion of HER-2- specific CD8+ T cells were defective in neu/N mice. Immune cell infiltrates of untreated tumor-bearing neu/N mice expressed high numbers of PD1 and OX40 receptors on their CD8+ T cells, and PD-L1 was highly expressed on both myeloid and tumor cells. Modulating PD-L1 and OX40 receptor signaling combined with intratumoral ADU S-100 administration enhanced HER-2-specific CD8+ T-cell activity, clearing tumors in 40% of neu/N mice. Thus, intratumoral STING agonists could potently prime tumor antigen-specific CD8+ T-cell responses, and adding PD-L1 blockade and OX40 receptor activation can overcome antigen-enforced immune tolerance to induce tumor regression.

UR - http://www.scopus.com/inward/record.url?scp=85020641723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020641723&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0284

DO - 10.1158/2326-6066.CIR-16-0284

M3 - Article

C2 - 28483787

AN - SCOPUS:85020641723

VL - 5

SP - 468

EP - 479

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 6

ER -